Clinical Trials for Pancreas Cancer

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors including HNSCC, pancreatic adenocarcinoma, NSCLC, HR+/HER2− breast cancer post‑CDK4/6 inhibitor, or platinum‑resistant high‑grade serous ovarian/related cancers receive the oral CDK7 inhibitor GTAEXS617 (transcription/cell‑cycle regulator) as monotherapy or combined with standard-of-care regimens. Eligible patients have ECOG 0–1 and adequate organ function; study explores safety, PK, and preliminary activity with tumor biopsies required.

ClinicalTrials.gov ID: NCT05985655

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma (ECOG 0–2) without prior pancreatic radiation receive stereotactic-like adaptive radiation therapy in 5 every-other-day fractions after optional induction chemotherapy. The trial escalates ART dose to biologically aggressive tumor regions while sparing organs-at-risk, with primary focus on grade ≥3 GI toxicity and secondary measures of local control and survival.

ClinicalTrials.gov ID: NCT06984562

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma who have disease control after 4–6 months of first-line chemotherapy (FOLFIRINOX/mFOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel) are randomized to standard post-induction management (continue chemo, standard-dose chemoradiation with 5-FU/capecitabine, or observation) versus dose‑escalated radiation (preferably 5 fractions; or 25 fractions with optional 5-FU/capecitabine), with chemotherapy completion to 6 months as needed. No investigational drugs are used; the trial tests whether higher-dose, precision RT improves survival.

ClinicalTrials.gov ID: NCT06958328

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic PDAC and cancer-associated cachexia (ECOG 0–1) beginning next cycle of first-line nab-paclitaxel/gemcitabine or (m)FOLFIRINOX are randomized to add ponsegromab, a subcutaneous anti–GDF-15 monoclonal antibody aimed at improving appetite/weight and function, versus placebo. Investigational therapy is given Q4W alongside standard chemotherapy; exclusions include reversible anorexia causes, CNS metastases, significant cardiac dysfunction, severe hepatic/renal impairment, and tube or parenteral feeding.

ClinicalTrials.gov ID: NCT06989437

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or recurrent pancreatic adenocarcinoma, ECOG 0–1, and no prior systemic therapy for metastatic disease receive first-line gemcitabine and nab-paclitaxel plus nivolumab and investigational imzokitug. Imzokitug is an anti-CCR8 antibody designed to deplete CCR8-positive tumor regulatory T cells.

ClinicalTrials.gov ID: NCT07226856

A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 metastatic pancreatic ductal adenocarcinoma who have a documented SWI/SNF chromatin-remodeling gene alteration (e.g., ARID1A/ARID1B, PBRM1, SMARCA4, SMARCB1) and have received exactly one prior systemic line for metastatic disease and are immunotherapy-naïve. Patients receive cemiplimab (anti–PD-1 checkpoint inhibitor) plus gemcitabine chemotherapy until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT06790602

A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (TRIDENT)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed (within 6 weeks), previously untreated metastatic pancreatic adenocarcinoma with measurable disease (RECIST 1.1) and ECOG 0–1 (excluding prior gemcitabine/nab-paclitaxel exposure for PDAC, significant neuropathy, chronic steroid need, active HIV/HBV/HCV, uncontrolled CNS mets, and known BRCA mutations) receive first-line nab-paclitaxel plus gemcitabine. Relacorilant, an investigational selective glucocorticoid receptor antagonist/modulator aimed at reducing cortisol-driven GR signaling and taxane resistance, is given orally 150 mg daily for 3 days around each chemotherapy dose in 28-day cycles until progression or toxicity.

ClinicalTrials.gov ID: NCT07259317

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma that is tissue-confirmed KRAS wild type and BRAF V600E wild type, ECOG 0–2, who have progressed on/intolerant of exactly one prior systemic cytotoxic regimen for advanced disease. Patients are randomized to investigator-chosen second-line chemotherapy (nal-IRI/5-FU/LV, irinotecan/5-FU/LV, or nab-paclitaxel/gemcitabine) with or without panitumumab, an anti-EGFR monoclonal antibody that blocks EGFR signaling.

ClinicalTrials.gov ID: NCT06998940

Phase Ib Randomized Study of Gemcitabine (G) With Nab-paclitaxel With or Without Pitavastatin (P) in the Maintenance Treatment of Unresectable Pancreatic Adenocarcinoma (uPDAC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic, recurrent, or locally advanced unresectable pancreatic adenocarcinoma without progression after 2–4 cycles of prior gemcitabine-based therapy receive gemcitabine plus nab-paclitaxel with escalating daily oral pitavastatin. Pitavastatin is an HMG-CoA reductase inhibitor being studied for potential antitumor effects via mevalonate pathway inhibition, with the goal of defining a recommended phase 2 dose and safety profile.

ClinicalTrials.gov ID: NCT07549958

GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated metastatic or unresectable pancreatic adenocarcinoma, microsatellite-stable/mismatch-repair–proficient and BRAF V600E–wild-type colorectal adenocarcinoma, or hepatocellular carcinoma are eligible if they have ECOG 0–1 and BMI ≥25 kg/m². Weekly semaglutide, a GLP-1 receptor agonist, is added to first-line modified FOLFIRINOX for pancreatic cancer, FOLFOX or FOLFIRI with or without bevacizumab for colorectal cancer, or tremelimumab plus durvalumab for hepatocellular carcinoma.

ClinicalTrials.gov ID: NCT07627191